Santersus completes first clinical trial for sepsis and Covid-19 treatment

Santersus AG announces the successful completion of their first in human clinical trials relating to Sepsis and COVID-19.

  • First trial started in Feb 2021 in Sepsis/COVID-19
  • Recruitment completed in September 2021 with 10 patients
  • Interim analysis showed safe, easy to apply, confirmed the reduction in NETs with a strong temporal association with clinical improvement

Related links

About Santersus

About VolitionRx Limited

If you would like to learn more about our technology, please contact Santersus team at